{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:57:56Z","timestamp":1791068276154,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.euroneuro.2007.11.005","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T22:51:02Z","timestamp":1199314262000},"page":"448-454","source":"Crossref","is-referenced-by-count":52,"title":["Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT1A receptors"],"prefix":"10.1016","volume":"18","author":[{"given":"Hiroko","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsui","family":"Kunitachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Shirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2007.11.005_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/026988110401800304","article-title":"A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment","volume":"18","author":"Bantick","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1476-5381.1991.tb12342.x","article-title":"Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia","volume":"103","author":"Bill","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","article-title":"5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia","volume":"15","author":"Burnet","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib6","first-page":"121","article-title":"Perospirone (Sumitomo Pharmaceuticals)","volume":"3","author":"De Paulis","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-006-0543-8","article-title":"Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635","volume":"189","author":"Frankle","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0028-3908(85)90153-4","article-title":"The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function","volume":"24","author":"Goodwin","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","article-title":"Alterations in the cortical serotonergic system in schizophrenia: a postmortem study","volume":"42","author":"Gurevich","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-003-1761-y","article-title":"The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications","volume":"174","author":"Harrison","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1568015043357011","article-title":"Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs","volume":"4","author":"Hashimoto","year":"2004","journal-title":"Curr. Med. Chem. \u2014 CNS Agents"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2006.09.055","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of \u03b17 nicotinic receptors","volume":"553","author":"Hashimoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.euroneuro.2007.07.009","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS.","volume":"18","author":"Hashimoto","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective a7 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1254\/jjp.53.321","article-title":"Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine-2 and dopamine-2 antagonistic actions","volume":"53","author":"Hirose","year":"1990","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/npp.1993.32","article-title":"Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia","volume":"8","author":"Joyce","year":"1993","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib25","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1254\/jjp.54.478","article-title":"Binding profile of SM-9018, a novel antipsychotic candidate","volume":"54","author":"Kato","year":"1990","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/(SICI)1097-4547(19961215)46:6<697::AID-JNR7>3.0.CO;2-A","article-title":"Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain","volume":"46","author":"Kia","year":"1996","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopsych.2003.09.017","article-title":"Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia","volume":"55","author":"Lopez-Figueroa","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1476-5381.1992.tb14457.x","article-title":"Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants","volume":"107","author":"Martin","year":"1992","journal-title":"Br. J. Pharmacol."},{"issue":"2 Suppl","key":"10.1016\/j.euroneuro.2007.11.005_bib31","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(01)01344-9","article-title":"Efficacy of antipsychotic agents at human 5-HT1A receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation","volume":"428","author":"Newman-Tancredi","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200115040-00006","article-title":"Perospirone","volume":"15","author":"Onrust","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-003-1515-x","article-title":"The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice","volume":"170","author":"Sakaue","year":"2003","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.jcp.0000236659.93415.4a","article-title":"Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 5-HT2 and dopamine D2 receptor occupancy in the living human brain","volume":"26","author":"Sekine","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1254\/jphs.93.114","article-title":"Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor","volume":"93","author":"Shiwa","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","article-title":"Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation","volume":"21","author":"Sprouse","year":"1999","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00726-006-0374-2","article-title":"The 5-HT1A receptor active compounds (R)-8-OH-DPAT and (S)-UH-301 modulate auditory evoked EEG responses in rats","volume":"31","author":"Stevens","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00210-004-1005-7","article-title":"Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo","volume":"371","author":"Sullivan","year":"2005","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib41","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","article-title":"The effect of tandospirone, a serotonin-1A agonist, on memory function in schizophrenia","volume":"49","author":"Sumiyoshi","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2007.11.005_bib44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archpsyc.59.6.514","article-title":"Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635","volume":"59","author":"Tauscher","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2007.11.005_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0031-9384(02)00936-8","article-title":"Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction","volume":"77","author":"Volk","year":"2002","journal-title":"Physiol. Behav."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X07002192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X07002192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:51:29Z","timestamp":1630446689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X07002192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0924977X07002192"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2007.11.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}